Nkarta (NKTX)
NASDAQ:NKTX
Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$3.47
-$0.05(-2.07%)
At close: 4:00 PM EST
$3.47
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.63 - $2.81
Previous CloseN/A
Volume369.36K
Average Volume (3M)613.52K
Market Cap
$172.52M
Enterprise Value$284.16M
Total Cash (Recent Filing)$276.28M
Total Debt (Recent Filing)$76.42M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 07, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,290,490
10 Day Avg. Volume602,762
30 Day Avg. Volume613,519
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-125.90
Enterprise Value/Ebitda-2.78
Forecast
1Y Price Target
$12.50Price Target Upside260.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthAnalyst highlights a sizable cash balance that reduces financing risk and supports continued clinical development without immediate capital raises.
Regulatory And Trial AccessFDA agreement to allow outpatient administration and reduced monitoring expands eligible trial sites to include community rheumatology centers, accelerating enrollment and broadening patient access.
Safety ProfileTrial reported no cytokine release syndrome or neurotoxicity, supporting a differentiated safety advantage of NK cell therapy versus CAR T therapies that could improve physician and patient uptake.
Bears Say
Clinical Data VisibilityUncertainty about the magnitude and durability of preliminary patient data creates visibility risk and complicates interpretation of early clinical outcomes.
CompetitionAnalyst warns that a rival NK cell program targeting rheumatoid arthritis could set a high efficacy benchmark, making that indication more competitive and increasing comparison risk for NKX019.
Operating ExpensesOperating expenses exceeded expectations due to higher research and development spending, increasing financial pressure and potentially necessitating additional funding.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.63 and its highest was $2.81 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $172.52M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is May 07, 2026 which is in 18 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Mar 25, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.06.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.35.
How many shares outstanding does Nkarta have?
Nkarta has 71,290,490 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 0.469%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (260.23% Upside)
$12.50 (260.23% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 125.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 10.8%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.71%
12-Months-Change
Fundamentals
Return on Equity
-30.02%
Trailing 12-Months
Asset Growth
-16.74%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$12.50
▲(260.23% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---